Relación entre carga parasitaria y linfocitos Th1 en biopsias de piel de perros con leishmaniosis
Resumen
Palabras clave
Texto completo:
Descargar el archivo PDFReferencias
Abbas AK, Murphy KM, Sher A. 1996. Functional diversity of helper T lymphocytes. Nature 383: 787-793.
Akuffo H, Maasho K, Britton S. 1996. Immunity to human leishmaniasis. Parasitology of the 21st Century, CAB
International 23-33.
Alexander J, Bryson K. 2005. T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett 99: 17-23.
Antoine JC, Prina E, Courret N, Lang T. 2004. Leishmania spp.: on the interactions they establish with antigenpresenting cells of their mammalian hosts. Adv Parasitol 58: 1-68.
Bhattacharya P, Ali N. 2013. Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis. Rev Soc Bras Med Trop 46: 128-134.
Banchereau J et al. 2000. Immunobiology of dendritic cells. Ann Rev Immunol 18: 767-811.
Bogdan C, Rollinghoff M, Diefenbach A. 2000. The role of nitric oxide in innate immunity. Immunol Rev 173: 17-26.
Brandonisio O et al. 2002. Macrophage chemotactic protein-l macrophage inflammatory protein-l alpha induce nitric oxide release and enhance parasite killing in Leishmania infantum infected human macrophages. Clin Exp Med 2: 125-129.
Carvalho EM, Bacellar O, Barral A, Badaro R, Johnson WD. 1989. Antigen-specific immuno suppression in visceral leishmaniasis is cell mediated. J Clin Invest 83: 860-864.
Costa DL et al. 2013. Serum cytokines associated with severity
and complications of kala-azar. Pathog Glob Health 107: 78-87.
Dujardin JC et al. 2008. Spread of vector-borne diseases and neglect of leishmaniasis, Europe Emerg Infect Dis 14:1013-1018.
Lima GM et al. 1998. The role of polymorphonuclear leukocytes in the resistance to cutaneous leishmaniasis. Immunol Lett 64: 145-151.
Lockesley RM, Louis JA. 1992. Immunology of leishmaniasis. Curr Opin Immunol 4: 413-418.
Manna PP, Chakrabarti G, Bandyopadhyay S. 2010. Innate immune defense in visceral leishmaniasis: cytokine mediated protective role by allogeneic effector cell. Vaccine 28: 803-810.
Murray HW. 1997. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J Infect Dis 175: 1477-1479.
Murray HW, Berman JD, Davies CR, Saravia NG. 2005. Advances in leishmaniasis. Lancet 366: 1561-1577.
Nylen S, Sacks D. 2007. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28: 378-384.
Peruhype MV et al. 2005. Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand J Immunol 62: 487-495.
Reis AB et al. 2006. Parasite density and impaired biochemical / hematological status are associated with severe clinical aspects of canine visceral leishmaniasis. Res Vet Sci 81: 68-75.
Reis AB et al. 2009. Systemic and compartmentalized immune response in canine visceral leishmaniasis. Vet Immunol Immunopathol 128: 87-95.
Santos GM et al. 2002. Cytokine expression during the outcome of canine experimental infection by Leishmania infantum. Vet Immunol Immunopathol 88: 21-30.
Vangisbergen KP, Geijtenbeek TB, Vankooyk Y. 2005. Close encounters of neutrophils and DCs. Trends Immunol 26: 626-631.
Vangriensven J, Diro E. 2012 Visceral leishmaniasis. 2012. Infect Dis Clin North Am 26: 309-322.
Vonstebut E, Udey MC. 2004. Requirements for Th1-dependent immunity against infection with Leishmania major. Microbes Infect 6: 1102-1109.
DOI: http://dx.doi.org/10.30972/vet.3114610